OBJECTIVE: To further understand the role of angiogenic growth factors in the development of cerebral cavernous malformations (CCMs) and arteriovenous malformations (AVMs), we investigated endothelial cell (EC) expression of receptors for vascular endothelial growth factor (VEGF) and angiopoietin systems in patients with surgically resected lesions. METHODS: Paraffin-embedded sections of five AVMs, CCMs, and normal control brain tissue samples were stained immunohistochemically with antibodies to von Willebrand factor and CD31 (to characterize ECs) and angiogenesis growth factor receptors Flt-1 (VEGF-R1), Flk-1 (VEGF-R2), Tie-1, and Tie-2. We counted large and small vessels in each specimen, assessed each specimen's immunoexpression of each antigen, and analyzed differences between CCMs, AVMs, and the normal control brain tissue samples. RESULTS: The ECs of CCMs, AVMs, and normal control brain tissue samples expressed the von Willebrand factor uniformly, but the ECs of CCMs were largely negative for CD31 (P < 0.05). Flk-1, Flt-1, and Tie-2 were not expressed in the control brain tissue samples. The proportion of immunopositive vessels to VEGF receptors Flk-1 and Flt-1 was significantly greater in AVMs and CCMs than in the control brain tissue samples (P < 0.05). Tie-2 in AVMs and CCMs was expressed in a higher percentage of immunopositive vessels than in the control brain tissue samples, but the difference was not statistically significant. Tie-1 was expressed in rare vessels of all lesion types and control brain tissue samples. CONCLUSION: ECs of CCMs do not seem to express CD31 to the same extent that AVMs and normal brain tissue do. AVMs and CCMs show greater expression of VEGF receptors, but not of angiopoietin receptors, than normal brain tissue does.
OBJECTIVE: To further understand the role of angiogenic growth factors in the development of cerebral cavernous malformations (CCMs) and arteriovenous malformations (AVMs), we investigated endothelial cell (EC) expression of receptors for vascular endothelial growth factor (VEGF) and angiopoietin systems in patients with surgically resected lesions. METHODS:Paraffin-embedded sections of five AVMs, CCMs, and normal control brain tissue samples were stained immunohistochemically with antibodies to von Willebrand factor and CD31 (to characterize ECs) and angiogenesis growth factor receptors Flt-1 (VEGF-R1), Flk-1 (VEGF-R2), Tie-1, and Tie-2. We counted large and small vessels in each specimen, assessed each specimen's immunoexpression of each antigen, and analyzed differences between CCMs, AVMs, and the normal control brain tissue samples. RESULTS: The ECs of CCMs, AVMs, and normal control brain tissue samples expressed the von Willebrand factor uniformly, but the ECs of CCMs were largely negative for CD31 (P < 0.05). Flk-1, Flt-1, and Tie-2 were not expressed in the control brain tissue samples. The proportion of immunopositive vessels to VEGF receptors Flk-1 and Flt-1 was significantly greater in AVMs and CCMs than in the control brain tissue samples (P < 0.05). Tie-2 in AVMs and CCMs was expressed in a higher percentage of immunopositive vessels than in the control brain tissue samples, but the difference was not statistically significant. Tie-1 was expressed in rare vessels of all lesion types and control brain tissue samples. CONCLUSION: ECs of CCMs do not seem to express CD31 to the same extent that AVMs and normal brain tissue do. AVMs and CCMs show greater expression of VEGF receptors, but not of angiopoietin receptors, than normal brain tissue does.
Authors: I J Rhyu; J A Bytheway; S J Kohler; H Lange; K J Lee; J Boklewski; K McCormick; N I Williams; G B Stanton; W T Greenough; J L Cameron Journal: Neuroscience Date: 2010-03-06 Impact factor: 3.590
Authors: Sergey I Nikolaev; Sandra Vetiska; Ximena Bonilla; Emilie Boudreau; Suvi Jauhiainen; Behnam Rezai Jahromi; Nadiya Khyzha; Peter V DiStefano; Santeri Suutarinen; Tim-Rasmus Kiehl; Vitor Mendes Pereira; Alexander M Herman; Timo Krings; Hugo Andrade-Barazarte; Takyee Tung; Taufik Valiante; Gelareh Zadeh; Mike Tymianski; Tuomas Rauramaa; Seppo Ylä-Herttuala; Joshua D Wythe; Stylianos E Antonarakis; Juhana Frösen; Jason E Fish; Ivan Radovanovic Journal: N Engl J Med Date: 2018-01-03 Impact factor: 91.245
Authors: Robert Shenkar; Palamadai N Venkatasubramanian; Jin-cheng Zhao; H Hunt Batjer; Alice M Wyrwicz; Issam A Awad Journal: Neurosurgery Date: 2008-10 Impact factor: 4.654
Authors: Richard Milner; Stephanie Hung; Bernadette Erokwu; Paula Dore-Duffy; Joseph C LaManna; Gregory J del Zoppo Journal: Mol Cell Neurosci Date: 2008-02-13 Impact factor: 4.314
Authors: Amy L Akers; Eric Johnson; Gary K Steinberg; Joseph M Zabramski; Douglas A Marchuk Journal: Hum Mol Genet Date: 2008-12-16 Impact factor: 6.150
Authors: Wuttipong Tirakotai; Sandra Fremann; Niels Soerensen; Wolfgang Roggendorf; Adrian M Siegel; Hans Dieter Mennel; Yuan Zhu; Helmut Bertalanffy; Ulrich Sure Journal: Childs Nerv Syst Date: 2006-02-18 Impact factor: 1.475